
Importance Older adults with advanced chronic kidney disease (CKD) face consequential decisions about whether to initiate dialysis, yet advance care planning (ACP), the communication that prepares patients for such decisions, is documented infrequently in ambulatory settings. Objective To determine whether a video decision aid about treatment options for advanced CKD, combined with patient-created video declarations, increases ACP documentation among older adults with advanced CKD. Design, Setting, and Participants This multicenter, parallel-group randomized clinical trial was conducted at 12 ambulatory clinics from June 2021 to March 2025, with 12-month follow-up. Participants were adults 65 years or older with advanced CKD. Outcome assessors were masked to group assignment. Data were analyzed in April 2026. Interventions Intervention participants viewed a certified video decision aid depicting 3 treatment options for advanced CKD (hemodialysis, peritoneal dialysis, and conservative kidney management) and then created a video declaration, a recorded statement of goals, values, and treatment preferences in video, audio, or written format, that was sent to their treating clinician. Control participants received usual medical care. Main Outcomes and Measures The primary outcome was ACP documentation in the electronic health record within 12 months of enrollment or death, whichever came sooner. Documentation was ascertained by validated natural language processing-assisted human adjudication. Prespecified secondary outcomes included documented discussion of kidney failure treatment options and stated treatment preferences. Results A total of 453 patients were included (228 intervention [50.3%] and 225 control [49.7%]; mean [SD] age, 78.8 [6.4] years; 190 women [41.9%]; 4 American Indian or Alaska Native [1.1%], 8 Asian [1.8%], 38 Black [8.4%], 35 Hispanic or Latino [7.7%], 3 Native Hawaiian or other Pacific Islander [0.7%], and 375 White [82.8%] individuals). At 12 months, ACP documentation was higher in the intervention group than the control group (56.6% vs 40.0%; rate difference, 16.6%; 95% CI, 7.5%-25.7%; P < .001), as was documented discussion of kidney failure treatment options (46.1% vs 31.6%; rate difference, 14.5%; 95% CI, 5.6%-23.4%; P = .001). After viewing the video, fewer intervention participants than controls at enrollment were undecided about treatment (30 of 227 [13.2%] vs 92 of 223 [41.3%]), and more preferred conservative kidney management (115 of 227 [50.7%] vs 71 of 223 [31.8%]; P < .001 for the overall distribution). Conclusions and Relevance This randomized clinical trial found that, among older adults with advanced CKD, a video decision aid increased ACP documentation and reduced the proportion of patients who were undecided about treatment. Trial Registration ClinicalTrials.gov Identifier: NCT04347629
Importance Cancer drugs are frequently approved based on uncertain benefits and risks that are not communicated to patients. Objective To evaluate the effect of communicating uncertainties about the benefits and risks of new cancer drugs on changes in individuals' hypothetical decisions to take the drug. Design, Setting, and Participants Two randomized clinical trials recruited online a demographically diverse sample of US adults (census matched for age, sex, education, income, and race and ethnicity) from May 9 to July 26, 2025. Intervention Plain-language statements describing uncertainties about drug benefits and risks. Trial 1 randomized participants to 1 of 5 uncertainties: (1) single-arm trial design, (2) unrepresentative population in terms of race and ethnicity, (3) short study duration, (4) surrogate end point, or (5) no noticeable improvement. Trial 2 randomized participants to 1, 2, 3, or 4 uncertainties or to a control group. Main Outcomes and Measures The primary outcome in trial 1 was changes in hypothetical decisions to take a new cancer drug (within-group difference), while in trial 2 the primary outcome was the change in between-group differences in hypothetical decisions (control vs intervention groups). Secondary outcomes included perceived treatment effectiveness, worry associated with taking the drug, and trust in the information and the US Food and Drug Administration. Results A total of 6272 adults were included in the primary analysis (3102 [49.5%] women). In trial 1, learning about uncertainties reduced hypothetical decisions to take the drug by a mean of 10.1 percentage points (pp; 95% CI, -11.7 to -8.5 pp; P < .001). The reduction in hypothetical decisions to take the drug was observed for all uncertainties, including among those in the group that learned that it was unknown whether patients would notice an improvement with the drug (-14.1 pp; 95% CI, -17.9 to -10.4 pp; P < .001) and those who learned that the drug was not studied in patients of similar race or ethnicity (-12.8 pp; 95% CI, -16.4 to -9.2; P < .001). In trial 2, hypothetical decisions to take the drug decreased with each additional uncertainty, demonstrating a dose-dependent effect. Learning about uncertainties reduced perceived effectiveness and trust but did not affect worry. Conclusions and Relevance In 2 randomized clinical trials including a demographically diverse sample of US adults, learning about common uncertainties with a new cancer drug's benefits and risks reduced hypothetical decisions to take the drug.
Background Patients undergoing cardiac surgery are at risk of perioperative conduction system damage leading to permanent placement of a cardiac electronic implantable device (CIED) which is a common complication following cardiac surgery. Studies evaluating the long-term outcomes following permanent pacemaker implantation in cardiac surgery patients are contradictory and inconsistent. The current study aimed to evaluate the long-term outcome across the spectrum of cardiac surgery in a nationwide contemporary setting.Methods All adult patients in Sweden, without previous CIED who had cardiac surgery between 2006 and 2020 were included. Data was obtained from nationwide registries. Cox proportional hazards models were used to account for comorbid conditions and perioperative characteristics and to evaluate the association between permanent pacemaker or implantable cardioverter defibrillator (ICD) implantation and the risk of all-cause mortality, cardiovascular mortality and heart failure hospitalisation.Results Among 76 223 patients (mean age 67.8 years, 25% female), 2150 (2.8%) received a permanent pacemaker and 348 (0.5%) received an ICD within 30 days after surgery. During a mean follow-up of 6.8 years (SD 10.7), pacemaker implantation was associated with a higher risk of all-cause mortality (adjusted HR (aHR) 1.09, 95% CI 1.01 to 1.19) and heart failure hospitalisation (aHR 1.36, 95% CI 1.22 to 1.52). Cardiovascular mortality showed a similar but statistically non-significant trend. ICD implantation was not associated with all-cause mortality but was associated with increased risks of heart failure hospitalisation and cardiovascular mortality. Subgroup analyses did not show any significant interactions between comorbid conditions and outcomes.Conclusion Permanent pacemaker implantation after cardiac surgery was associated with a higher risk of all-cause mortality and heart failure hospitalisation. These findings were consistent across cardiac surgical subtypes and underscore the need for careful long-term surveillance for these patients.
QuestionAre previously assessed clinical risk scores useful to inform medical decisions to surveil for cirrhosis or hepatocellular carcinoma (HCC) in patients with noncirrhotic steatotic liver disease (SLD)?FindingsThis cohort study compared 9 clinical risk scores in 853 131 adults with imaging-confirmed SLD at risk of both cirrhosis and HCC and found that the steatosis-associated fibrosis estimator (SAFE) score at a threshold of 29.5 demonstrated the greatest net benefit to predict incident cirrhosis-it identified 1.9 additional individuals who developed cirrhosis within 10 years per every 100 at-risk individuals. Clinical risk scores for HCC demonstrated minimal benefit to inform the decision to initiate screening for HCC in the absence of cirrhosis.MeaningThese findings suggest that the SAFE score can be used to counsel patients with SLD and to inform decision-making regarding repeat assessments for cirrhosis. ImportanceMost individuals with steatotic liver disease (SLD) do not develop advanced liver disease. Multiple risk scores for SLD-associated cirrhosis and hepatocellular carcinoma (HCC) have been proposed, but their utility to inform decisions about surveillance for advanced liver disease is unknown.ObjectiveTo compare the clinical utility of SLD risk scores for predicting cirrhosis and hepatocellular carcinoma in patients with noncirrhotic steatotic liver disease.Design, Setting, and ParticipantsThis cohort study used data from the national US Veterans Affairs health system of adults with imaging-confirmed SLD without viral hepatitis or primary liver disease from 2008 and 2020. Nine clinical risk scores were calculated at the time of the first imaging results that demonstrated hepatic steatosis. Individuals were followed up until cirrhosis, HCC, death, or 6 months after last follow-up visit. Data were analyzed between November 1, 2025, and May 11, 2026.ExposuresNine risk scores evaluated for prediction of cirrhosis or HCC within 10 years were: (1) ALBI, albumin-bilirubin; (2) aMAP, age-male-albumin-bilirubin-platelet; (3) APRI, the aspartate aminotransferase-to-platelet ratio; (4) BARD, body mass index, age, alanine aminotransferase-to-aspartate aminotransferase ratio, and diabetes; (5) FIB-4, fibrosis-4 index; (6) NFS, nonalcoholic fatty liver disease fibrosis; (7) SAFE, steatosis-associated fibrosis estimator; and 2 additional scores.Main Outcomes and MeasuresFirst diagnosis of cirrhosis and first diagnosis of HCC identified using VA and Medicare diagnosis codes and data from the VA Cancer Registry. Cox proportional hazards models were used to calculate time-dependent 10-year probabilities of each outcome predicted by 9 risk scores. Decision curves were generated for each outcome by calculating the net benefit, a weighted measure of true and false positives over a prespecified range of risk thresholds at which a clinician may reasonably recommend intervention. Nine risk scales were used to quantify the risk of cirrhosis or HCC within 10 years.ResultsThe analysis included 853 131 patients (median [IQR] age, 61 [51-68] years; 62 168 females [7.3%] and 790 965 males [92.7%]) whose median (IQR) BMI was 31.3 (27.6-35.5) and 275 898 (32.3%) had diabetes; of these, 33 794 (3.96%) developed cirrhosis and 2978 (0.35%) developed HCC within 10 years. The FIB-4, APRI, and SAFE scores demonstrated the greatest discrimination of cirrhosis risk, while the SAFE, Tate, and FIB-4 scores demonstrated the greatest discrimination of HCC risk. The SAFE score demonstrated the greatest net benefit predicting cirrhosis. A score of 29.5 corresponded to a 10-year cirrhosis risk of 2.5% and yielded a net benefit of 0.019, or 1.9 additional individuals who develop cirrhosis per 100 individuals classified as at-risk patients. At a 0.25% 10-year risk of HCC, the SAFE score had a net benefit of 0.0016 (1.6 additional true positives per 1000 individuals).Conclusions and RelevanceThe findings of this cohort study show that the SAFE score may inform decisions to repeat screening for cirrhosis in patients with SLD. Clinical risk scores for HCC demonstrated minimal utility to inform HCC screening decisions for patients with noncirrhotic SLD. This cohort study assesses the clinical utility of steatotic liver disease risk scores for predicting cirrhosis and hepatocellular carcinoma in patients with noncirrhotic steatotic liver disease.
Background: Acute ST-segment elevation myocardial infarction (STEMI) with high thrombus burden often shows impaired myocardial perfusion despite successful epicardial recanalization. Intracoronary recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) may reduce microvascular obstruction and preserve ventricular function, but evidence is limited. Methods: This single-center retrospective cohort study included 136 STEMI patients with high thrombus burden undergoing primary PCI between May 2022 and February 2025. Patients receiving intracoronary rhTNK-tPA (n=62) were compared with controls receiving standard PCI alone (n=74). The primary endpoint was left ventricular regional wall motion status within 7 days after PCI, assessed by WMSI and normal ventricular wall motion. Secondary endpoints included cTFC, ST-segment resolution, final TIMI flow grade, and clinical and safety outcomes. Results: Baseline characteristics were generally comparable. The rhTNK-tPA group had lower WMSI values (P<0.001) and a higher incidence of normal ventricular wall motion (41.7% vs. 19.6%; P=0.014). rhTNK-tPA was also associated with lower post-PCI cTFC (18.18 ± 6.91 vs. 21.24 ± 9.20; P=0.033) and higher ST-segment resolution (83.9% vs. 68.9%; P=0.043), while final TIMI grade 3 flow was similar. In multivariable analysis, rhTNK-tPA was independently associated with lower odds of ventricular wall motion abnormalities (OR=0.214; 95% CI, 0.106–0.433; P<0.001). MACE were infrequent, and no intracranial hemorrhage occurred. Conclusion: Adjunctive intracoronary rhTNK-tPA during primary PCI was associated with better early preservation of regional wall motion and improved reperfusion indices without an observed increase in major bleeding. Keywords: ST-segment elevation myocardial infarction; primary percutaneous coronary intervention; intracoronary thrombolysis; recombinant human TNK tissue-type plasminogen activator.